Sulfonamide hypersensitivity

Immunology and Allergy Clinics of North America

Volumn 24, Issue 3, 2004, Pages 477-490

  Slatore, Christopher G ^a   Tilles, Stephen A ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Northwest Asthma & Allergy Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ADRENALIN; AMPICILLIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIOXIDANT; BENZODIAZEPINE; CELECOXIB; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; DIURETIC AGENT; FUROSEMIDE; INDAPAMIDE; PENICILLIN G; SULFONAMIDE; SULFONYLUREA; TOLBUTAMIDE;

ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANXIETY; CONGESTIVE HEART FAILURE; CROSS ALLERGY; CROSS REACTION; DESENSITIZATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; EDEMA; EPSTEIN BARR VIRUS; FEVER; FLUSHING; HEMOGLOBINURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; PRIORITY JOURNAL; PUSTULE; RASH; RESPIRATORY DISTRESS; REVIEW; SEDATION; SERUM SICKNESS; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VIRUS INFECTION;

CROSS REACTIONS; DESENSITIZATION, IMMUNOLOGIC; DIAGNOSIS, DIFFERENTIAL; DRUG HYPERSENSITIVITY; HIV INFECTIONS; HUMANS; SULFONAMIDES;

EID: 3042701366     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2004.03.011     Document Type: Review

References (60)

1. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients. JAMA. 279:1998;1200-1205
2. deShazo R.D., Kemp S.F. Allergic reactions to drugs and biologic agents. JAMA. 278:1997;1895-1906
3. Zinner S.H., Mayer K.H. Sulfonamides and trimethoprim. Mandell G.L., Bennett J.E., Dolin R. Mandell: principles and practice of infectious diseases. 5th edition:2000;394-397 Churchill Livingstone, Philadelphia
4. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis. 4:1982;426-428
5. Kucera C.M., Greenberger P.A. Adverse drug reactions: treatment and prevention. Hosp Med. 32:1996;11-24
6. Tilles S.A., Slatore C.G. Hypersensitivity reactions to non-beta-lactam antibiotics. Clin Rev Allergy Immunol. 24:2003;221-228
7. Roujeau J.C., Huynh T.N., Bracq L., et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol. 123:1987;1171-1173
8. Gould I.M., Jappy B. Trends in hospital antimicrobial prescribing after 9 years of stewardship. J Antimicrob Chemother. 45:2000;913-917
9. Montanaro A. Sulfonamide allergy. Immunol Allergy Clin N Am. 18:1998;843-850
10. Bardicth-Crovo P., Chaisson R.E. Adverse reactions to therapy for HIV infection. Emerg Med Clin North Am. 13:1995;133-146
11. Tilles S.A. Practical issues in the management of hypersensitivity reactions: sulfonamides. S Med J. 94:2001;817-824
12. Shear N.H., Spielberg S.P., Grant D.M., et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 105:1986;179-184
13. Cribb A.E., Miller M., Tesoros A., Spielberg S.P. Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. Mol Pharmacol. 38:1990;744-751
14. Cribb A.E., Spielberg S.P. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther. 51:1992;522-526
15. Cribb A.E., Spielberg S.P., Griffin G.P. N4-hydroxylation of sulfamethoxazole by cytochrome p450 of the cytochrome p4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat liver microsomes. Drug Metab Dispos. 23:1995;406-414
16. Naisbitt D.J., Hough S.J., Gill H.J., Pirmohamed M., Kitteringham N.R., Park B.K. Cellular disposition of sulfamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol. 126:1999;1393-1401
17. Burkhart C., von Greyerz S., Depta J.P., Naisbitt D.J., Britschgi M., Park K.B., et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T cells. Br J Pharmacol. 132:2001;623-630
18. Manchanda T., Hess D., Dale L., Ferguson S.G., Rieder M.J. Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol Pharmacol. 62:2002;1011-1026
19. Naisbitt D.J., Gordon S.F., Pirmohamed M., Burkhart C., Cribb A.E., Pichler W.J., et al. Antigenicity and immunogenicity of sulfamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol. 133:2001;295-305
20. Naisbitt D.J., Farrell J., Gordon S.F., Maggs J.L., Burkhart C., Pichler W.J., et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol. 62:2002;628-637
21. Lee B.L., Wong D., Benowitz N.L., Sullam P.M. Altered patterns of drug-metabolism in patients with acquired immunodeficiency syndrome. Clin Parmacol Ther. 53:1993;529-535
22. O'Neil W.M., MacArthur R.D., Farrough M.J., Doll M.A., Fretland A.J., Hein D.W., et al. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J Clin Pharmacol. 42:2002;613-619
23. Alfirevic A., Stalford A.C., Vilar F.J., Wilkins E.G., Park B.K., Pirmohamed M. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol. 55:2003;158-165
24. Walmsley S.L., Winn L.M., Harrison M.L., et al. Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. AIDS. 11:1997;1689-1697
25. Naisbitt D.J., Vilar F.J., Stalford A.C., et al. Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection. AIDS Res Hum Retroviruses. 16:2000;1929-1938
26. Pirmohamed M., Alfirevic A., Vilar J., Stalford A., Wilkins E.G.L., Sim E., et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics. 10:2000;705-713
27. Walmsley S.L., Khorashed S., Singer J., Djurdjev O. A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). J Acquir Immune Defic Syndr Hum Retrovirol. 19:1998;498-505
28. Pirmohamed M., Naisbitt D.J., Gordon F., Park B.K. The danger hypothesis - potential role in idiosyncratic drug reactions. Toxicology. 181-182:2002;55-63
29. Haverkos H.W., Amsel Z., Drotman D.P. Adverse virus-drug interactions. Rev Infect Dis. 13:1991;697-704
30. Cribb A.E., Lee B.L., Trepanier L.A., et al. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev. 15:1996;9-50
31. Bond C.A. Skin disorders I. Koda-Kimble M.A., Young L. Applied therapuetics: the clinical use of drugs. 1992;1-64 Applied Therapeutics, Vancouver
32. Cheriyan S., Patterson R., Greenberger P.A., et al. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc. 16:1995;151-155
33. Kollef M., Goodenberger D. Critical care and medical emergencies. Ewald G.A., McKenzie C.R. Manual of medical therapeutics. 28th edition:1995;184-235 Little Brown, Boston
34. Patterson R., DeSwarte R.D., Greenberger P.A., et al. Individual drugs or problems: summary of useful techniques. Drug allergy and protocols for management of drug allergies. 1995;9-18 OceanSide Publications, Providence (RI)
35. Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med. 331:1994;1272-1285
36. Toll L.L., Hurlbut K.M., editors. POISINDEX system. Greenwood Village (CO): Micromedex; edition expires, 2004
37. Rawlins M.D., Thompson W. Mechanisms of adverse drug reactions. Daview D.M. Textbook of adverse drug reactions. 1991;18-45 Oxford University Press, New York
38. Absy M., Glatt A.E. Antibiotic allergy: inaccurate history taking in a teaching hospital. South Med J. 87:1994;805-807
39. Pilzer J.D., Burke T.G., Mutnick A.H. Drug allergy assessment at a university hospital and clinic. Am J Health Syst Pharm. 53:1996;2970-2975
40. Gruchalla R.S., Sullivan T.J. Detection of human IgE to sulfamethoxazole skin testing with sulfamethoxazoyl-poly-L-tyrosine. J Allergy Clin Immunol. 88:1991;784-792
41. Neuman M.G., Malkiewicz I.M., Shear N.H. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin Biochem. 33:2000;517-524
42. Neuman M.G., Malkiewicz I.M., Phillips E.J., Rachlis A.R., Ong D., Yeung E., et al. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Monit. 24:2002;728-736
43. Greenberger P.A. Drug challenge and desensitization protocols. Immunol Allergy Clin N Am. 18:1998;759-772
44. Douglas R., Spelman D., Czarny D., et al. Successful desensitization of two patients who previously developed Stevens-Johnson syndrome while receiving trimethoprim-sulfamethoxazole. Clin Infect Dis. 25:1997;1480
45. Koski J.M. Desensitization to sulphasalazine in patients with arthritis. Clin Exp Rheumatol. 11:1993;169-170
46. Moreno J.N., Poblete R.B., Maggio C., et al. Rapid oral desensitization for sulfonamides in patients with acquired immunodeficiency syndrome. Ann Allergy Asthma Immunol. 74:1995;140-146
47. Rich J.D., Sullivan T., Greineder D., et al. Trimethoprim/ sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons. Ann Allergy Asthma Immunol. 79:1997;409-414
48. Leoung G.S., Stanford J.F., Giordano M.F., Stein A., Torres R.A., Giffen C.A., et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis. 184:2001;992-997
49. Shapiro L.E., Knowles S.R., Weber E., Neuman M.G., Shear N.H. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf. 26:2003;187-195
50. Strom B.L., Schinnar R., Apter A.J., Margolis D.J., Lautenbach E., Hennessy S., et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 349:2003;1628-1635
51. Hansbrough J.R., Wedner H.J., Chaplin D.D. Anaphylaxis to intravenous furosemide. J Allergy Clin Immunol. 80:1987;538-541
52. Sullivan T.J. Cross-reactions among furosemide, hydrochlorothiazide, and sulfonamides. JAMA. 265:1991;120-121
53. Barrio M., Tornero P., Baeza M. Cross-reactivity among the para-amine group in sulfonamide-induced urticaria and fixed drug eruption [abstract]. J Allergy Clin Immunol. 87:1991;364A
54. Stock J.G. Sulfonamide hypersensitivity and acetazolamide. Arch Opthalmol. 108:1990;634-635
55. Schnewweiss F. Cross-sensitivity between sulfonamides and furosemide [letter]. Clin Pharm. 2:1983;510
56. Stricker B., Biriell C. Skin reactions and fever with indapamide. BMJ. 295:1987;1313-1314
57. DeBarrio M., Tornero P., Zubeldia J.M., et al. Fixed drug eruption induced by indapamide: cross-reactivity with sulfonamides. J Investig Allergol Clin Immunol. 8:1998;253-255
58. Shenfield G.M., Jacka J. Adverse drug reaction [letter]. Lancet. 57:2001;561
59. Bretza J. Thrombocytopenia due to sulfonamide cross-sensitivity. WMJ. 81:1982;21-23
60. Britschgi M., Steiner U., Schmid S. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest. 107:2001;1433-1441